François Audenet1, Adam M Farkas2, Harry Anastos1, Matthew D Galsky2, Nina Bhardwaj2, John P Sfakianos3. 1. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. john.sfakianos@mountsinai.org.
Abstract
PURPOSE: To explore the immune phenotype of peripheral blood mononuclear cells (PBMC) in patients with high-risk non-muscle invasive bladder cancer (NMIBC). METHODS: We prospectively collected blood samples from patients with high-risk NMIBC treated at our institution. PBMC were analyzed by flow cytometry to determine the frequency of T cells and NK cells and the expression of immunoregulatory molecules (Tim-3, TIGIT and PD-1). PBMC from healthy donors (HD) were included for comparison, and associations with response to BCG were investigated. RESULTS: A total of 38 patients were included, 19 BCG responders and 19 BCG refractory. Compared to 16 PBMC from HD, the frequency of total NK cells was significantly higher in patients with NMIBC [15.2% (IQR: 11.4, 22.2) vs. 5.72% (IQR: 4.84, 9.79); p = 0.05], whereas the frequency of T cells was not statistically different. Both Tim-3 and TIGIT expressions were significantly higher in NMIBC compared to HD, particularly in NK cells [13.8% (11.0; 22.4) vs. 5.56% (4.20; 10.2) and 34.9% (18.9; 53.5) vs. 1.82% (0.63; 5.16), respectively; p < 0.001]. Overall, the expression of PD-1 in all cell types was low in both NMIBC patients and HD. The immune phenotype was not significantly different before and after initiation of BCG. However, the proportion of CD8+ T cells before BCG was significantly higher in responders. CONCLUSION: The immune phenotype of PBMC from patients with high-risk NMIBC was significantly different from HD, regardless of the presence of disease or the initiation of BCG. Peripheral CD8+ T cells could play a role in response to BCG.
PURPOSE: To explore the immune phenotype of peripheral blood mononuclear cells (PBMC) in patients with high-risk non-muscle invasive bladder cancer (NMIBC). METHODS: We prospectively collected blood samples from patients with high-risk NMIBC treated at our institution. PBMC were analyzed by flow cytometry to determine the frequency of T cells and NK cells and the expression of immunoregulatory molecules (Tim-3, TIGIT and PD-1). PBMC from healthy donors (HD) were included for comparison, and associations with response to BCG were investigated. RESULTS: A total of 38 patients were included, 19 BCG responders and 19 BCG refractory. Compared to 16 PBMC from HD, the frequency of total NK cells was significantly higher in patients with NMIBC [15.2% (IQR: 11.4, 22.2) vs. 5.72% (IQR: 4.84, 9.79); p = 0.05], whereas the frequency of T cells was not statistically different. Both Tim-3 and TIGIT expressions were significantly higher in NMIBC compared to HD, particularly in NK cells [13.8% (11.0; 22.4) vs. 5.56% (4.20; 10.2) and 34.9% (18.9; 53.5) vs. 1.82% (0.63; 5.16), respectively; p < 0.001]. Overall, the expression of PD-1 in all cell types was low in both NMIBCpatients and HD. The immune phenotype was not significantly different before and after initiation of BCG. However, the proportion of CD8+ T cells before BCG was significantly higher in responders. CONCLUSION: The immune phenotype of PBMC from patients with high-risk NMIBC was significantly different from HD, regardless of the presence of disease or the initiation of BCG. Peripheral CD8+ T cells could play a role in response to BCG.
Authors: David D'Andrea; Marco Moschini; Kilian Gust; Mohammad Abufaraj; Mehmet Özsoy; Romain Mathieu; Francesco Soria; Alberto Briganti; Morgan Rouprêt; Pierre I Karakiewicz; Shahrokh F Shariat Journal: Clin Genitourin Cancer Date: 2017-03-27 Impact factor: 2.872
Authors: Ines Pires da Silva; Anne Gallois; Sonia Jimenez-Baranda; Shaukat Khan; Ana C Anderson; Vijay K Kuchroo; Iman Osman; Nina Bhardwaj Journal: Cancer Immunol Res Date: 2014-02-11 Impact factor: 11.151
Authors: Matthew H Spitzer; Yaron Carmi; Nathan E Reticker-Flynn; Serena S Kwek; Deepthi Madhireddy; Maria M Martins; Pier Federico Gherardini; Tyler R Prestwood; Jonathan Chabon; Sean C Bendall; Lawrence Fong; Garry P Nolan; Edgar G Engleman Journal: Cell Date: 2017-01-19 Impact factor: 41.582
Authors: Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour Journal: J Exp Med Date: 2010-09-06 Impact factor: 14.307
Authors: F Solorzano-Ibarra; A G Alejandre-Gonzalez; P C Ortiz-Lazareno; B E Bastidas-Ramirez; A Zepeda-Moreno; M C Tellez-Bañuelos; N Banu; O J Carrillo-Garibaldi; A Chavira-Alvarado; M R Bueno-Topete; S Del Toro-Arreola; J Haramati Journal: Clin Exp Immunol Date: 2021-01-18 Impact factor: 5.732
Authors: Kyrollis Attalla; Adam M Farkas; Harry Anastos; Francois Audenet; Matthew D Galsky; Nina Bhardwaj; John P Sfakianos Journal: Urol Oncol Date: 2020-07-12 Impact factor: 2.954